Biodrugs

Papers
(The H4-Index of Biodrugs is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond223
Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry119
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis83
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor75
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery69
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis55
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome50
Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design48
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making48
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?35
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202233
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies32
CAR-T Cells and the Kidney: Insights from the WHO Safety Database31
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic31
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart30
Acknowledgement to Referees30
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials29
Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy29
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data28
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review28
Malaria Vaccines: Progress to Date27
Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance25
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects24
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer24
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network24
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?24
0.042765855789185